Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region

Market Overview - The global central nervous system (CNS) therapeutics market is estimated to be USD 144.3 million in 2024 and is expected to reach USD 431.0 million by 2035, with a CAGR of 10.46% during the forecast period 2025-2035 [2] - Growth is driven by factors such as the rising prevalence of neurological disorders, improvements in drug development and approvals, increased investments in R&D, growing telemedicine and digital therapeutics adoption, and the growing use of personalized medicine [2] Disease Segmentation - The mental health therapeutics segment accounted for the highest revenue in 2024 due to the increasing prevalence of mental health disorders such as depression, anxiety, and schizophrenia, along with growing awareness and acceptance of mental health treatments [4] - The neurodegenerative diseases segment is predicted to grow at the fastest CAGR during the forecast period due to the rising incidence of conditions like Alzheimer's and Parkinson's disease, advancements in disease-modifying therapies, and a growing aging population [4] Drug Class Segmentation - The CNS stimulants segment accounted for the highest revenue in 2024 due to the growing demand for ADHD treatments and the increasing use of stimulants for managing attention-deficit hyperactivity disorder in both children and adults [5] - The anticonvulsants segment is predicted to grow at the fastest CAGR during the forecast period due to its widespread application in treating epilepsy, bipolar disorder, and neuropathic pain, along with the development of new-generation anticonvulsants with fewer side effects and improved efficacy [6] Distribution Channel Segmentation - The hospital pharmacies segment accounted for the highest revenue in 2024 due to the increasing number of hospital admissions for severe neurological and psychiatric conditions, coupled with the availability of specialized CNS treatments in hospital settings [7] - The retail pharmacies segment is predicted to grow at the fastest CAGR during the forecast period due to the expanding reach of retail pharmacy chains, rising over-the-counter availability of CNS medications, and the growing preference for outpatient treatment, particularly in emerging markets [7] Regional Analysis - North America is anticipated to have the highest revenue share during the forecast period due to the well-established healthcare infrastructure, high prevalence of neurological and mental health disorders, significant investments in R&D, and the presence of key market players [8] - The Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period due to rapidly increasing healthcare spending, growing awareness of neurological and psychiatric disorders, expanding access to advanced treatments, and a large, aging population [8] Industry Trends - Biopharmaceutical companies are increasingly focusing on the development of novel therapeutics for the CNS, including disease-modifying drugs, biologics, and gene therapies [3] - For instance, in March 2024, Ultomiris received FDA approval as the first long-acting C5 complement inhibitor specifically for treating adults with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) [3] - In May 2024, AC Immune and Takeda signed an exclusivity contract for the Alzheimer's immunotherapy ACI-24.060, which included an upfront payment of USD 100 million and possible milestones of USD 2.1 million [4] - In October 2024, AbbVie announced a deal to buy Aliada Therapeutics, a biotechnology company developing treatments for difficult CNS diseases using a novel blood-brain barrier (BBB)-crossing technology [5] Key Players - The report includes exhaustive company profiles of the top 10+ market players, including Pfizer Inc, Johnson & Johnson (Janssen Pharmaceuticals), Roche Holding AG, Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb, Sanofi, AbbVie Inc, Merck & Co Inc, Biogen Inc, AstraZeneca PLC, GlaxoSmithKline (GSK), Amgen Inc, H Lundbeck A/S, and Teva Pharmaceutical Industries Ltd [9]